Skip to Main Content

INFORMATION FOR

Pamela Kunz, MD

Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology; Vice Chief, Diversity, Equity, and Inclusion, Medical Oncology

Research Summary

Dr. Kunz has developed broad investigative programs in the field of neuroendocrine tumors (NETs), encompassing clinical trials, population sciences, and translational correlates.

Extensive Research Description

Dr. Kunz has developed broad investigative programs in the field of neuroendocrine tumors (NETs), encompassing clinical trials, population sciences, and translational correlates.

Coauthors

Research Interests

Neuroendocrine Tumors

Selected Publications

  • Gender analysis of oncology expert participation on online professional platforms.Kunzman J, Henry E, Housri N, Kamran S, Kunz P, Lee L, LoConte N, Burt L. Gender analysis of oncology expert participation on online professional platforms. Journal Of Clinical Oncology 2022, 40: 350-350. DOI: 10.1200/jco.2022.40.28_suppl.350.
  • 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 StudyMyrehaug S, Singh S, Pavel M, Kunz P, de Herder W, Herrmann K, D’Amelio A, Santoro P, Folitar I, Ferone D. 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study Radiotherapy And Oncology 2022, 174: s40-s41. DOI: 10.1016/s0167-8140(22)04371-7.
  • Examination of speakership gender disparity at an international oncology conference.Caro J, Boatwright C, Li X, Fiocco C, Stempel J, Stoeckle J, Smithy J, Betof Warner A, Shum E, Sabari J, Malhotra J, Chan N, Spencer K, Kunz P, Goldberg J, Mehnert J. Examination of speakership gender disparity at an international oncology conference. Journal Of Clinical Oncology 2022, 40: 11002-11002. DOI: 10.1200/jco.2022.40.16_suppl.11002.
  • A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).Kunz P, Graham N, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Rubin D, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, Wong T, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 40: 4004-4004. DOI: 10.1200/jco.2022.40.16_suppl.4004.
  • Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyenRuszniewski P, Strosberg J, Caplin M, Kunz P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, van Cutsem E, Seregni E, Duarte H, Niepel D, Demange A, Krenning E. Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyen Nuklearmedizin - NuclearMedicine 2022, 46: 49-50. DOI: 10.1016/j.mednuc.2022.01.004.
  • Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
  • 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analysesRuszniewski P, Caplin M, Kunz P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Demange A, Mutevelic S, Krenning E, Strosberg J. 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses Annals Of Oncology 2021, 32: s911-s912. DOI: 10.1016/j.annonc.2021.08.184.
  • Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015Cheng E, Cheng E, Blackburn H, Ng K, Ng K, Spiegelman D, Irwin M, Ma X, Gross C, Tabung F, Tabung F, Giovannucci E, Giovannucci E, Kunz P, Llor X, Billingsley K, Meyerhardt J, Meyerhardt J, Ahuja N, Fuchs C. Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015 Cancer Research 2021, 81: 898-898. DOI: 10.1158/1538-7445.am2021-898.
  • O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETsStrosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Pulido E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E. O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs Annals Of Oncology 2021, 32: s217-s218. DOI: 10.1016/j.annonc.2021.05.006.
  • Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E, group O. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. Journal Of Clinical Oncology 2021, 39: 4112-4112. DOI: 10.1200/jco.2021.39.15_suppl.4112.
  • MA12.09 Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid TumorsSun T, Codima A, Hwang G, Hornbacker K, Pancirer D, Lui N, Raj R, Kunz P, Padda S. MA12.09 Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid Tumors Journal Of Thoracic Oncology 2021, 16: s179. DOI: 10.1016/j.jtho.2021.01.260.
  • NANETS/SNMMI consensus statement on patient selection and appropriate use of 177 Lu-DOTATATE peptide receptor radionuclide therapyHope T, Bodei L, Chan J, El-Haddad G, Fidelman N, Kunz P, Mailman J, Menda Y, Metz D, Mittra E, Pryma D, Reidy-Lagunes D, Singh S, Strosberg J. NANETS/SNMMI consensus statement on patient selection and appropriate use of 177 Lu-DOTATATE peptide receptor radionuclide therapy Chinese Journal Of Nuclear Medicine And Molecular Imaging 2020, 40: 679-685. DOI: 10.3760/cma.j.cn321828-20200227-00071.
  • Analyse de la PFS de l’étude NETTER-1 chez des patients présentant une TNE intestinale dans des sous-groupes de mauvais pronostic avec atteinte hépatiqueRuszniewski P, Strosberg J, Kunz P, Hendifar A, Yao J, Bushnel D, Kulke M, Baum R, Caplin M, Delpassand E, Hobday T, Verslype C, Benson A, Polack B, Beilei H, Santaro P, Krenning E, group N. Analyse de la PFS de l’étude NETTER-1 chez des patients présentant une TNE intestinale dans des sous-groupes de mauvais pronostic avec atteinte hépatique Nuklearmedizin - NuclearMedicine 2020, 44: 96-97. DOI: 10.1016/j.mednuc.2020.01.108.
  • Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).Duan H, Ninatti G, Girod B, Ferri V, Kunz P, Fisher G, Moradi F, Davidzon G, Franc B, Iagaru A, Mari C. Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). Journal Of Clinical Oncology 2020, 38: 623-623. DOI: 10.1200/jco.2020.38.4_suppl.623.
  • Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms.Sun T, Van Hummelen P, Martin B, Xia C, Lee H, Zhao L, Hornbacker K, Ji H, Kunz P. Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms. Journal Of Clinical Oncology 2020, 38: 624-624. DOI: 10.1200/jco.2020.38.4_suppl.624.
  • Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.Chan D, Bergsland E, Chan J, Gadgil R, Halfdanarson T, Hornbacker K, Kelly V, Kunz P, McGarrah P, Raj N, Reidy D, Thawer A, Whitman J, Wu L, Singh S. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. Journal Of Clinical Oncology 2019, 37: 321-321. DOI: 10.1200/jco.2019.37.4_suppl.321.
  • P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice ConsensusSingh S, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus Journal Of Thoracic Oncology 2018, 13: s575. DOI: 10.1016/j.jtho.2018.08.841.
  • 1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 studyStrosberg J, Hendifar A, Yao J, Kulke M, O’Dorisio T, Caplin M, Baum R, Kunz P, Hobday T, Wolin E, Mittra E, Oberg K, Ruszniewski P, Polack B, He B, Barton D, Santaro P, Krenning E. 1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study Annals Of Oncology 2018, 29: viii471. DOI: 10.1093/annonc/mdy293.009.
  • 1322P The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)Segelov E, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Singh S. 1322P The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET) Annals Of Oncology 2018, 29: viii473. DOI: 10.1093/annonc/mdy293.015.
  • A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2018, 36: 4004-4004. DOI: 10.1200/jco.2018.36.15_suppl.4004.
  • A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution.Pumpalova Y, Kozak M, von Eyben R, Kunz P, Fisher G, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution. Journal Of Clinical Oncology 2018, 36: e15573-e15573. DOI: 10.1200/jco.2018.36.15_suppl.e15573.
  • Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies.Mou E, Wittenberg T, Kunz P, Schapira L. Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies. Journal Of Clinical Oncology 2018, 36: 75-75. DOI: 10.1200/jco.2018.36.7_suppl.75.
  • A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.Pumpalova Y, Kozak M, von Eyben R, Fisher G, Kunz P, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Journal Of Clinical Oncology 2018, 36: 710-710. DOI: 10.1200/jco.2018.36.4_suppl.710.
  • Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.Kardosh A, Tseng D, Sahaf B, Zomet A, Krupa J, Fisher G, Wang D, Mackall C, Kunz P. Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. Journal Of Clinical Oncology 2018, 36: tps191-tps191. DOI: 10.1200/jco.2018.36.4_suppl.tps191.
  • Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension periodHorsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Warner R, Kunz P, Pulido E, Valle J, Dillon J, Lapuerta P, Banks P, Jackson S, Pavel M. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period Endocrine Abstracts 2017 DOI: 10.1530/endoabs.52.p14.
  • Weight change associated with telotristat ethyl in the treatment of carcinoid syndromeWeickert M, Kaltsas G, Horsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Lombard-Bohas C, Fleming R, Kittur A, Arnold K, Kulke M, Welin S, Warner R, Yang Q. Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome Endocrine Abstracts 2017 DOI: 10.1530/endoabs.52.p25.
  • 438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trialStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Öberg K, Sierra M, Ruszniewski P, Krenning E. 438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial Annals Of Oncology 2017, 28: v146. DOI: 10.1093/annonc/mdx368.010.
  • 440PD Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension periodHörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Warner R, Kunz P, Pulido E, Valle J, Dillon J, Lapuerta P, Banks P, Jackson S, Pavel M. 440PD Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period Annals Of Oncology 2017, 28: v147. DOI: 10.1093/annonc/mdx368.012.
  • Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.Fisher G, Pommier R, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Journal Of Clinical Oncology 2017, 35: 4088-4088. DOI: 10.1200/jco.2017.35.15_suppl.4088.
  • Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.Weickert M, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Warner R, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang Q, Kulke M. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Journal Of Clinical Oncology 2017, 35: e15692-e15692. DOI: 10.1200/jco.2017.35.15_suppl.e15692.
  • Abstract No. 38 Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor: Stratification by tumor burdenAbdelRazek M, Hwang W, Abdelmaksoud M, Louie J, Kothary N, Kunz P, Sze D. Abstract No. 38 Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor: Stratification by tumor burden Journal Of Vascular And Interventional Radiology 2017, 28: s19. DOI: 10.1016/j.jvir.2016.12.625.
  • Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Journal Of Clinical Oncology 2017, 35: 348-348. DOI: 10.1200/jco.2017.35.4_suppl.348.
  • Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.Pommier R, Fisher G, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Journal Of Clinical Oncology 2017, 35: 378-378. DOI: 10.1200/jco.2017.35.4_suppl.378.
  • NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup AnalysisStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera S, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis Endocrine Abstracts 2016 DOI: 10.1530/endoabs.47.oc8.
  • Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension periodHorsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Valle J, Fleming D, Lapuerta P, Banks P, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.oc3.
  • Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviewsAnthony L, Horsch D, Ervin C, Kulke M, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz D, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang Q, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.p11.
  • Effectiveness of Radiation Therapy for Low- to Intermediate-Grade Neuroendocrine TumorsCarter J, Aggarwal S, Radish K, Allen J, Koong A, Chang D, Loo B, Diehn M, Kunz P, Gensheimer M. Effectiveness of Radiation Therapy for Low- to Intermediate-Grade Neuroendocrine Tumors International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e202-e203. DOI: 10.1016/j.ijrobp.2016.06.1100.
  • 420PD NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysisStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. 420PD NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis Annals Of Oncology 2016, 27: vi137. DOI: 10.1093/annonc/mdw369.05.
  • 422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndromeKulke M, Hörsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Bohas C, Kunz P, Grande E, Valle J, Lapuerta P, Banks P, Jackson S, Jiang W, Biran T, Pavel M. 422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.07.
  • 423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, Kunz P, Gabrail N, Hinson J, Orlemans E. 423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs) Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.08.
  • 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT studyWolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study Annals Of Oncology 2016, 27: vi143. DOI: 10.1093/annonc/mdw369.23.
  • 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label studyFisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study Annals Of Oncology 2016, 27: vi144. DOI: 10.1093/annonc/mdw369.25.
  • Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster AwardFisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award The American Journal Of Gastroenterology 2016, 111: s457-s458. DOI: 10.14309/00000434-201610001-01052.
  • Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT StudyWolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study The American Journal Of Gastroenterology 2016, 111: s468. DOI: 10.14309/00000434-201610001-01076.
  • Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension periodHörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Jackson S, Zambrowicz B, Sands A, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period Zeitschrift Für Gastroenterologie 2016, 54 DOI: 10.1055/s-0036-1587175.
  • O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatateStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Chaplin M, Baum R, Kunz P, Hobday T, Oberg K, Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E, Hendifar A. O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate Annals Of Oncology 2016, 27: ii121. DOI: 10.1093/annonc/mdw198.09.
  • Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).Peng S, Saunders L, Bheddah S, Williams S, Aggarwal R, Shea J, Lee E, Huang J, Zemek A, Longacre T, Ball D, Scaife C, Nelkin B, Anthony L, Kunz P, Small E, Dylla S. Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC). Journal Of Clinical Oncology 2016, 34: 11611-11611. DOI: 10.1200/jco.2016.34.15_suppl.11611.
  • NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E, Kunz P. NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE. Journal Of Clinical Oncology 2016, 34: 4005-4005. DOI: 10.1200/jco.2016.34.15_suppl.4005.
  • NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. Journal Of Clinical Oncology 2016, 34: 194-194. DOI: 10.1200/jco.2016.34.4_suppl.194.
  • Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKETReid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Stirn M, Caroen S, Parker C, Scicinski J. Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET Cancer Research 2016, 76: b26-b26. DOI: 10.1158/1538-7445.chromepi15-b26.
  • Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide TherapyFisher G, Wolin E, Kunz P, Liyanage N, Gomez-Panzani E, Lowenthal S, Pommier R, Shaheen M, Vinik A. Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy The American Journal Of Gastroenterology 2015, 110: s1007. DOI: 10.14309/00000434-201510001-02424.
  • 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)Kulke M, Horsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Banks P, Jackson S, Wheeler D, Zambrowicz B, Sands A, Pavel M. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) European Journal Of Cancer 2015, 51: s728. DOI: 10.1016/s0959-8049(16)31951-7.
  • Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancerReid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer 2015, ct119-ct119. DOI: 10.1158/1538-7445.am2015-ct119.
  • Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).Kulke M, Niedzwiecki D, Foster N, Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Journal Of Clinical Oncology 2015, 33: 4005-4005. DOI: 10.1200/jco.2015.33.15_suppl.4005.
  • A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Schrijver I, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2015, 33: tps4145-tps4145. DOI: 10.1200/jco.2015.33.15_suppl.tps4145.
  • Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors?Narayanan S, Kunz P. Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal Of Endocrine Oncology 2015, 2: 13-20. DOI: 10.2217/ije.14.37.
  • Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.
  • Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Single versus Multi-FractionPollom E, Alagappan M, Cox V, Kamaya A, Kunz P, Poultsides G, Visser B, Koong A, Chang D. Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Single versus Multi-Fraction International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s50. DOI: 10.1016/j.ijrobp.2014.05.184.
  • Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial.Nagpal S, Recht C, Imtiaz U, Bertrand S, Thomas R, Ajlan A, Pena J, Gershon M, Kunz P, Li G, Recht L. Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. Journal Of Clinical Oncology 2014, 32: 2096-2096. DOI: 10.1200/jco.2014.32.15_suppl.2096.
  • Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.Denlinger C, Sym S, Bendell J, Alsina M, Watkins D, Chao Y, Cubillo A, Kunz P, Sun W, Baeksgaard L, Chen L, Horgan K, Frye S, Kudla A, McDonagh C, Czibere A, Moyo V, Chibaudel B, Bang Y. Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Journal Of Clinical Oncology 2014, 32: tps4148-tps4148. DOI: 10.1200/jco.2014.32.15_suppl.tps4148.
  • Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal TractDiMaio M, Zemek A, Kwok S, Kunz P, Longacre T. Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract Gastroenterology 2014, 146: s-210-s-211. DOI: 10.1016/s0016-5085(14)60745-9.
  • A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.Kunz P, Nandoskar P, Koontz M, Ji H, Ford J, Balise R, Kamaya A, Rubin D, Fisher G. A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 115-115. DOI: 10.1200/jco.2014.32.3_suppl.115.
  • A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.Heestand G, Murphy J, Moughan J, Regine W, Luo J, Graber M, Kunz P, Fisher G, Guha C, Lin B, Mowat R, Gaur R, Buyyounouski M, Chen Y, Chang D, Koong A. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. Journal Of Clinical Oncology 2014, 32: 176-176. DOI: 10.1200/jco.2014.32.3_suppl.176.
  • Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors.Strosberg J, Jump H, Valone T, Weber J, Khandelwal V, Kunz P. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. Journal Of Clinical Oncology 2014, 32: 241-241. DOI: 10.1200/jco.2014.32.3_suppl.241.
  • Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.Pollom E, Alagappan M, Chan C, Shultz D, Kunz P, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 317-317. DOI: 10.1200/jco.2014.32.3_suppl.317.
  • Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors.Lin H, Longacre T, Khandelwal V, Balise R, Kunz P. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Journal Of Clinical Oncology 2013, 31: e15011-e15011. DOI: 10.1200/jco.2013.31.15_suppl.e15011.
  • Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors.Lin H, Longacre T, Khandelwal V, Balise R, Kunz P. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.4_suppl.154.
  • Penile metastases originating from a pancreatic primary tumor: a case reportTello T, Zeidan Y, Bush K, Schwartz E, Kunz P, Chang D. Penile metastases originating from a pancreatic primary tumor: a case report Journal Of Radiation Oncology 2012, 2: 107-112. DOI: 10.1007/s13566-012-0076-1.
  • A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine TumorsKunz P. A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine Tumors American Society Of Clinical Oncology Educational Book 2012, 271-274. DOI: 10.14694/edbook_am.2012.32.136.
  • Multimodality Therapy for Esophageal Cancer: The Benefit of ChemoradiationVossler S, Bavan B, Kunz P, Ford J, Fisher G, Whyte R, Koong A, Chang D. Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s309. DOI: 10.1016/j.ijrobp.2011.06.497.
  • Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.Smyth E, Enzinger P, Li J, Vincitore M, Lacy J, El-Rayes B, Kunz P, Ford J, Robinson E, Kelsen D, Shah M. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. Journal Of Clinical Oncology 2011, 29: 4056-4056. DOI: 10.1200/jco.2011.29.15_suppl.4056.
  • Long-term survivorship in gastric cancer.Kunz P, Gubens M, Fisher G, Ford J, Lichtensztajn D, Clarke C. Long-term survivorship in gastric cancer. Journal Of Clinical Oncology 2011, 29: 14-14. DOI: 10.1200/jco.2011.29.4_suppl.14.
  • Long-term survivorship in pancreatic adenocarcinoma.Gubens M, Kunz P, Fisher G, Ford J, Lichtensztajn D, Clarke C. Long-term survivorship in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 175-175. DOI: 10.1200/jco.2011.29.4_suppl.175.
  • The Evolution of Modern Systemic Agents for Colorectal CancerHeestand G, Kunz P, Fisher G. The Evolution of Modern Systemic Agents for Colorectal Cancer Radiation Medicine Rounds 2010, 1: 249-260. DOI: 10.5003/2151-4208.1.2.249.
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.Kunz P, Kuo T, Zahn J, Kaiser H, Norton J, Visser B, Longacre T, Ford J, Balise R, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. Journal Of Clinical Oncology 2010, 28: 4104-4104. DOI: 10.1200/jco.2010.28.15_suppl.4104.
  • A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer.He A, Kunz P, Pishvaian M, Colevas A, Hwang J, Clemens P, Messina M, Kaleta R, Abrahao F, Sikic B. A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer. Journal Of Clinical Oncology 2010, 28: e13090-e13090. DOI: 10.1200/jco.2010.28.15_suppl.e13090.
  • Treatment of pancreatic cancer in patients age 70 or older.Christman-Skieller C, Heestand G, Fisher G, Kunz P, Ford J, Columbo L, Chang D, Koong A. Treatment of pancreatic cancer in patients age 70 or older. Journal Of Clinical Oncology 2010, 28: e14590-e14590. DOI: 10.1200/jco.2010.28.15_suppl.e14590.
  • 37 Cancer of the StomachMinsky B, Ford J, Kunz P, Norton J. 37 Cancer of the Stomach 2010, 788-800. DOI: 10.1016/b978-1-4160-5897-7.00038-x.
  • Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric CancerMinn A, Fisher G, Ford J, Kunz P, Norton J, Koong A, Chang D. Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s259. DOI: 10.1016/j.ijrobp.2009.07.597.
  • Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II studyJhawer M, Kindler H, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah M. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study Journal Of Clinical Oncology 2009, 27: 4502-4502. DOI: 10.1200/jco.2009.27.15_suppl.4502.
  • Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experiencede Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.
  • Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experienceKunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.
  • Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the PancreasSchellenberg D, Kim J, Columbo L, Lee C, Fisher G, Kunz P, Maxim P, Goodman K, Chang D, Koong A. Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the Pancreas International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s127. DOI: 10.1016/j.ijrobp.2008.06.428.
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary resultsKunz P, Kuo T, Kaiser H, Norton J, Longacre T, Ford J, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results Journal Of Clinical Oncology 2008, 26: 15502-15502. DOI: 10.1200/jco.2008.26.15_suppl.15502.
  • An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancerKuo T, Cabebe E, Koong A, Norton J, Kunz P, Ford J, Kaiser H, Rogers J, Sikic B, Fisher G. An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer Journal Of Clinical Oncology 2008, 26: 15571-15571. DOI: 10.1200/jco.2008.26.15_suppl.15571.
  • Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancerCabebe E, Kuo T, Koong A, Welton M, Shelton A, Kunz P, Ford J, Sikic B, Kaiser H, Rogers J, Fisher G. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer Journal Of Clinical Oncology 2008, 26: 15019-15019. DOI: 10.1200/jco.2008.26.15_suppl.15019.

Clinical Trials